<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR4">
 <label>4.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ahmed</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Siman-Tov</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Keck</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Kortchak</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Bakovic</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Risner</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Lu</surname>
    <given-names>TK</given-names>
   </name>
   <name>
    <surname>Bhalla</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>de la Fuente-Nunez</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Narayanan</surname>
    <given-names>A</given-names>
   </name>
  </person-group>
  <article-title>Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections</article-title>
  <source>Antivir Res</source>
  <year>2019</year>
  <volume>164</volume>
  <fpage>61</fpage>
  <lpage>69</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.02.002</pub-id>
  <?supplied-pmid 30738837?>
  <pub-id pub-id-type="pmid">30738837</pub-id>
 </element-citation>
</ref>
